Clinical Trial Update: A Phase I Trial of a LTK63 Adjuvated Tuberculosis Nasal Subunit Vaccine (Ag85B-ESAT6) [Phase 1]

View source ↗

Summary

Phase I trial evaluating a nasal subunit tuberculosis vaccine with LTK63 adjuvant (Ag85B-ESAT6); the study is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• LTK63 Adjuvated Tuberculosis Nasal Subunit Vaccine (Ag85B-ESAT6)

Snippet

Sponsor: St George's, University of London | Conditions: Tuberculosis | Phase 1 | Status: TERMINATED